# Nebula Genomics Blockchain DNA Privacy

> Nebula Genomics, co-founded by Harvard geneticist George Church, uses blockchain technology for privacy-preserving genome sequencing. Users gain full control over their DNA data through smart contracts. Researchers can run analyses on encrypted data without ever seeing the raw data. EMD Serono piloted the platform for drug development data acquisition.

**Sector:** Quaternary sector · **Industry:** Biotechnology and genetic research · **Organisation:** Nebula Genomics · **Maturity level:** Concept

Canonical URL: https://www.sapientblock.com/en/use-cases/nebula-genomics-genomdaten-souveraen-kontrollieren

## Documentation status

- **Project status:** Concept
- **Evidence:** Evidence high
- **Editorial review:** Ufuk Avci, 15 April 2026

## Description

Nebula Genomics was co-founded in 2018 by Harvard geneticist George Church. The platform combines whole genome sequencing with blockchain-based data sovereignty. Users receive inalienable ownership rights to their genome data via a public ledger. Access rights are controlled via smart contracts. Compute-to-Data enables analysis on encrypted data. EMD Serono (Merck) piloted the platform. Publications in Nature Biotechnology and Blockchain in Healthcare Today.

Nebula Genomics addresses the fundamental problem of genomics: 23andMe and Ancestry monetise their customers' DNA data — Nebula reverses the model and returns control to the users.

## Benefits

- Pharmaceutical companies acquire genomic datasets for drug development without raw data access — GDPR compliant.
- Compute-to-Data significantly lowers legal barriers for genomic research.
- Users receive whole genome sequencing with full data sovereignty.
- Anonymous sequencing without identity disclosure is possible.
- Inalienable ownership rights to genome data documented via public ledger.
- Compute-to-Data enables analysis on encrypted data without exfiltration.
- Whole genome sequencing from $299 with full data control.
- Researchers conduct GWAS studies on encrypted cohorts without GDPR conflicts.

## Challenges

- Integration of Compute-to-Data into existing pharmaceutical research pipelines requires technical adjustments.
- Users must understand and manage wallet infrastructure — a technical hurdle for non-technical target groups.
- The acquisition by ProPhase Labs (2021, approx. $14.6 million) changed strategic priorities — the blockchain aspect is under further development.
- Regulatory frameworks for blockchain-based genomic data are not yet established.
- Bioinformaticians require training in privacy-preserving computation methods.

## Technology foundation

Blockchain ledger for ownership rights, Oasis Labs Secure Enclaves, homomorphic encryption, Compute-to-Data framework.

## Sources

- [Nebula Genomics](https://nebula.org)
- [Blockchain-enabled genomic data sharing](https://www.nature.com/articles/s41587-019-0085-3)
- [WIRED: This startup wants you to sell your genetic data on the blockchain (Nebula Genomics, George Church)](https://www.wired.com/story/nebula-genomics-zenome-encrypgen-george-church/)
- [FierceBiotech: George Church founds cryptocurrency-fueled genomics firm](https://www.fiercebiotech.com/biotech/george-church-founds-cryptocurrency-fueled-genomics-firm)